243 related articles for article (PubMed ID: 26716758)
1. Direct costs of care for hepatocellular carcinoma in patients with hepatitis C cirrhosis.
Tapper EB; Catana AM; Sethi N; Mansuri D; Sethi S; Vong A; Afdhal NH
Cancer; 2016 Mar; 122(6):852-8. PubMed ID: 26716758
[TBL] [Abstract][Full Text] [Related]
2. Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C.
Shimoda M; Ghobrial RM; Carmody IC; Anselmo DM; Farmer DG; Yersiz H; Chen P; Dawson S; Durazo F; Han S; Goldstein LI; Saab S; Hiatt J; Busuttil RW
Liver Transpl; 2004 Dec; 10(12):1478-86. PubMed ID: 15558585
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma: Can it be considered a controversial indication for liver transplantation in centers with high rates of hepatitis C?
Moya A; Berenguer M; Aguilera V; Juan FS; Nicolás D; Pastor M; López-Andujar R; Rayón M; Orbis F; Mora J; De Juan M; Carrasco D; Vila JJ; Prieto M; Berenguer J; Mir J
Liver Transpl; 2002 Nov; 8(11):1020-7. PubMed ID: 12424715
[TBL] [Abstract][Full Text] [Related]
4. Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor.
Vitale A; Farinati F; Burra P; Trevisani F; Giannini EG; Ciccarese F; Piscaglia F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Cabibbo G; Felder M; Sacco R; Morisco F; Missale G; Foschi FG; Gasbarrini A; Svegliati Baroni G; Virdone R; Chiaramonte M; Spolverato G; Cillo U;
Liver Transpl; 2015 Oct; 21(10):1250-8. PubMed ID: 26183802
[TBL] [Abstract][Full Text] [Related]
5. Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis.
Bozorgzadeh A; Orloff M; Abt P; Tsoulfas G; Younan D; Kashyap R; Jain A; Mantry P; Maliakkal B; Khorana A; Schwartz S
Liver Transpl; 2007 Jun; 13(6):807-13. PubMed ID: 17539001
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis.
Patel D; Terrault NA; Yao FY; Bass NM; Ladabaum U
Clin Gastroenterol Hepatol; 2005 Jan; 3(1):75-84. PubMed ID: 15645408
[TBL] [Abstract][Full Text] [Related]
7. Healthcare Costs Related to Treatment of Hepatocellular Carcinoma Among Veterans With Cirrhosis in the United States.
Kaplan DE; Chapko MK; Mehta R; Dai F; Skanderson M; Aytaman A; Baytarian M; D'Addeo K; Fox R; Hunt K; Pocha C; Valderrama A; Taddei TH;
Clin Gastroenterol Hepatol; 2018 Jan; 16(1):106-114.e5. PubMed ID: 28756056
[TBL] [Abstract][Full Text] [Related]
8. Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center.
Franssen B; Alshebeeb K; Tabrizian P; Marti J; Pierobon ES; Lubezky N; Roayaie S; Florman S; Schwartz ME
Ann Surg; 2014 Oct; 260(4):650-6; discussion 656-8. PubMed ID: 25203882
[TBL] [Abstract][Full Text] [Related]
9. Pricey pills for an even pricier problem.
Kwan SW
Cancer; 2016 Mar; 122(6):840-1. PubMed ID: 26716603
[No Abstract] [Full Text] [Related]
10. Efficacy and cost of a hepatocellular carcinoma screening program at an Australian teaching hospital.
Qian MY; Yuwei J R; Angus P; Schelleman T; Johnson L; Gow P
J Gastroenterol Hepatol; 2010 May; 25(5):951-6. PubMed ID: 20546449
[TBL] [Abstract][Full Text] [Related]
11. Prior Trans-arterial chemoembolization - A protective factor against rapid HCV recurrence post liver transplant in patients with HCV with HCC? - A Retrospective Cohort Study.
Vasavada B
Int J Surg; 2016 Jun; 30():132-5. PubMed ID: 27154618
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors of survival in patients with non-resectable hepatocellular carcinoma: hepatitis C versus miscellaneous etiology.
Abbas Z; Siddiqui AU; Luck NH; Hassan M; Mirza R; Naqvi A; Rizvi AH
J Pak Med Assoc; 2008 Nov; 58(11):602-7. PubMed ID: 19024130
[TBL] [Abstract][Full Text] [Related]
13. Health care costs associated with chronic hepatitis C virus infection in Ontario, Canada: a retrospective cohort study.
Wong WWL; Haines A; Bremner KE; Yao Z; Calzavara A; Mitsakakis N; Kwong JC; Sander B; Thein HH; Krahn MD
CMAJ Open; 2021; 9(1):E167-E174. PubMed ID: 33688024
[TBL] [Abstract][Full Text] [Related]
14. Non-resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention-to-treat and dropout from liver transplant waiting list.
Fisher RA; Maluf D; Cotterell AH; Stravitz T; Wolfe L; Luketic V; Sterling R; Shiffman M; Posner M
Clin Transplant; 2004 Oct; 18(5):502-12. PubMed ID: 15344951
[TBL] [Abstract][Full Text] [Related]
15. [Hepatocellular carcinoma: the significance of cirrhosis for treatment and prognosis--retrospective study].
Witjes CD; de Man RA; Eskens FA; Dwarkasing RS; Zondervan PE; Verhoef C; Ijzermans JN
Ned Tijdschr Geneeskd; 2010; 154():A1747. PubMed ID: 20719013
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma in HCV-infected patients awaiting liver transplantation: genes involved in tumor progression.
Mas VR; Maluf DG; Stravitz R; Dumur CI; Clark B; Rodgers C; Ferreira-Gonzalez A; Fisher RA
Liver Transpl; 2004 May; 10(5):607-20. PubMed ID: 15108252
[TBL] [Abstract][Full Text] [Related]
17. Timing of Antiviral Therapy in Candidates for Liver Transplant for Hepatitis C and Hepatocellular Carcinoma.
Saab S; Jimenez M; Fong T; Wu C; El Kabany M; Tong MJ
Exp Clin Transplant; 2016 Feb; 14(1):66-71. PubMed ID: 26581477
[TBL] [Abstract][Full Text] [Related]
18. Independent Predictors of Mortality and Resource Utilization in Viral Hepatitis Related Hepatocellular Carcinoma.
Golabi P; Jeffers T; Younoszai Z; Otgonsuren M; Sayiner M; Mishra A; Venkatesan C; Younossi ZM
Ann Hepatol; 2017; 16(4):555-564. PubMed ID: 28611258
[TBL] [Abstract][Full Text] [Related]
19. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis.
Arguedas MR; Chen VK; Eloubeidi MA; Fallon MB
Am J Gastroenterol; 2003 Mar; 98(3):679-90. PubMed ID: 12650806
[TBL] [Abstract][Full Text] [Related]
20. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.
Zanetto A; Shalaby S; Vitale A; Mescoli C; Ferrarese A; Gambato M; Franceschet E; Germani G; Senzolo M; Romano A; Angeli P; Rugge M; Farinati F; Forton DM; Cillo U; Burra P; Russo FP
Liver Transpl; 2017 Sep; 23(9):1103-1112. PubMed ID: 28544587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
